MedTrace Logo

Single Dose Escalation Study of PF-05190457 in Healthy Volunteers

NCT01247896 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 26

Last updated 2011-07-06

No results posted yet for this study

Summary

PF-05190457 is a novel compound proposed for the treatment of Type 2 diabetes mellitus. The purpose of the study is to evaluate the safety and tolerability of PF-05190457 after administration of a single dose to healthy volunteers and to evaluate the plasma drug concentrations after single dose in healthy volunteers.

Conditions

  • Diabetes Mellitus, Type II

Interventions

DRUG

PF-05190457

Single Dose 2 mg

DRUG

PF-05190457

Single Dose 10 mg

DRUG

PF-05190457

Single Dose 30 mg

DRUG

PF-05190457

Single Dose 100 mg

DRUG

PF-05190457

Single Dose 300 mg

DRUG

PF-05190457

Single Dose 600 mg

DRUG

PF-05190457

Single Dose - to be determined with food

DRUG

PF-05190457

Single Dose - to be determined

DRUG

Placebo

Single Dose Placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-06-30
Completion
2011-06-30

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01247896 on ClinicalTrials.gov